LAFAYETTE, Calif., June 12, 2023 /PRNewswire/ — Alexander Shulgin Research Institute (ASRI), a pioneering organization in the discovery of next generation psychedelic medicines, announces the identification of two lead compounds currently undergoing late-stage preclinical testing. ASRI plans to disclose further details of their initial lead compounds in a live press conference at the MAPS Psychedelic Science 2023 Conference in Denver, Colorado on June 21, 2023, at 11:30 am MT.
ASRI will share details about two promising lead compounds currently undergoing late-stage preclinical testing. These novel compounds demonstrate great potential in addressing unmet medical needs. The Institute is actively progressing towards initiating clinical trials and will continue to prioritize the highest standards of safety and efficacy throughout the development process. ASRI is committed to sharing relevant updates to their stakeholders, including the scientific community, investors and patients eagerly awaiting new therapeutic options.
ASRI stands at the forefront of the growing interest in the potential benefits of psychedelics, with a focus on applied therapeutics for neurological, neurodevelopmental, neuropsychiatric, pain syndromes, inflammation, and improved wellness. They are striving to make a positive impact on global healthcare. ASRI is a team of renowned experts in chemistry, pharmacology, and neuroscience with an unwavering commitment to improving patient outcomes and transforming lives by translating novel psychedelic compounds into potential therapies that address mental health and beyond. The Shulgin Vault contains over 500 compounds synthesized by Alexander “Sasha” Shulgin and ASRI scientists, offering a vast library of novel variations of phenylalkylamines, tryptamines, lysergamides, isoquinolines, cathinones, and more.
Dr. Nicholas Cozzi, ASRI Co-Founder and President, stated, “It has been a busy time for ASRI. In just two years, we have acquired the inventions, discoveries, and work product of Dr. Alexander ‘Sasha’ Shulgin, assembled a team of executives, scientists, and clinicians, synthesized dozens of novel molecules, and developed a robust preclinical testing cascade.”